TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Disability Rating Scale change
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Proportion of children with average hemoglobin ≥9.0 g/dL or average HbF ≥20%
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Quantitative Changes in OCT Central Thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Snellen Acuity Lines Gained/Lost
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Microbiologically Confirmed Tuberculosis Infection
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With HIV Infection
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of respiratory viral infection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Rate of CDI reoccurrence
Endpoint domain: Adverse events/effects
Primary endpoint: percentage of diabetic patients with pseudo-exfoliation syndrome
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ophthalmic outcomes
Primary endpoint: antibody levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Pulmonary Oxygenation Function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Changes of left ventricular ejection fraction (LVEF)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Angiographic in-stent % diameter stenosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Late loss at follow up
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Partial Onset Seizure Frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in Instrumental Activities of Daily Living (IADL)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Lane performance Variability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Vitamin D blood levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Psychological well being (depression, stress and anxiety)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Balance performance on the sensory organization test (SOT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bland-Altman estimate of bias and Limits of Agreement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maintenance of body weight
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Percentage Change From Baseline in VAS (Visual Analog Scale) With Air Stimulation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage Change From Baseline in VAS (Visual Analog Scale) With Cold Stimulation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage Change From Baseline in DPS (Dental Pain Scale) With Air Stimulation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage Change From Baseline in DPS (Dental Pain Scale) With Cold Stimulation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in Fridericia's Correction for QT Interval (QTcF)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: joint angles
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: movement acceleration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: movement pattern
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to Non-Infectivity by RT-PCR
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Time to Symptom progression in days as measured by NEWS scoring system
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to Symptom improvement as measured by NEWS scoring system
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Duration of Survival
Endpoint domain: Mortality/survival
Primary endpoint: 17-item Hamilton Depression Rating Scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: GAF (Global Assessment of Function)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Brachial artery caliber
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of Participants Who Initiated the HPV Vaccine Series
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Number of Participants Who Completed the HPV Vaccine Series
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Arterial blood gas parameters (pH, HCO3, PCO2, PO2)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: αIIbβ3 (GPIIb-IIIa) integrin activation changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Response according to WHO criteria
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: improvement of headache frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 24-hour gastroesophageal pH
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Number of Participants With Oxygen Saturations Below 92%
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Clinically relevant bleeds
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of death due to any cause
Endpoint domain: Mortality/survival
Primary endpoint: Change in PSQ Scores
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Maximum Observed Serum Concentration (Cmax) of Functional Dupilumab
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants With Investigator's Global Assessment (IGA) Score 0 or 1 at Week 16
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Percentage of Participants With Eczema Area and Severity Index (EASI) -75 (EASI-75) at Week 16
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Inflammation Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline in ratings of vaginal delivery forms
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Relative preference rankings of vaginal delivery forms
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Hypertrophy of left ventricle
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Acute Ablation Success
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Percentage of Participants With a Static Physician's Global Assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants Who Maintained a ≥90% Improvements in Psoriasis Area and Severity Index (PASI) 90
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Measure Your Medical Outcome Profile2 (MYMOP)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: total number of lumbar facet joints showing tenderness on palpation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: maximum active lumber extension angle
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Visual analogue score (VAS)
Endpoint domain: Life impact
Endpoint subdomain: Pain
Primary endpoint: Gastroesophageal reflux disease symptoms
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Ventilation defect percent (VDP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Physician's Global Assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Number of Unformed Bowel Movements in 24 Hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Change in global risk
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Motor and Sensory Scores of the ASIA Impairment Scale (AIS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change from baseline in the 4-week partial seizure rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Prevalence of surface samples positive for PA
Endpoint domain: Adverse events/effects
Primary endpoint: AUC of IMP percentage retention in the whole stomach
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Change of the rate of canine retraction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of anti-reflux surgery
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Rate of pharmacological anti-reflux treatment
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Post-operative complications requiring Neuro-ICU stay
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants Reporting Overall Flushing Events During the Overall Treatment Period
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants Reporting Gastrointestinal (GI) Events During the Overall Treatment Period
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Change from baseline Short Physical Performance Battery
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Proportion of HCPs aware of risk communications tools
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Level of knowledge and comprehension of identified risks
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: HCP and patient behaviours
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Atrogin-1 expression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Intramuscular Ras level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Positive Airway Pressure usage (hours/night)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prosthetic survival
Endpoint domain: Mortality/survival
Primary endpoint: Patients Outcome
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Incidence of Contrast-induced acute kidney injury (CI-AKI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Proportion of participants completing the study
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Postoperative gain of stereopsis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Weighted Mean Total Nasal Symptom Score (TNSS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain on the Visual Analog Scale (VAS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hormonal response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Percentage of ITT Population Experiencing Death Within 30 Days
Endpoint domain: Mortality/survival
Primary endpoint: Target Site Revascularization
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Need for Mechanical ventilation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Self-reported continuous smoking cessation
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in inflammatory or biochemical marker concentration in induced sputum
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Peripheral airway resistance and reactance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Nitric oxide concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Proportion of subjects with at least a 2 log drop in HCV RNA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of subjects achieving ACR 20 response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Anthropometrics
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in diet
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Type 2 myocardial infarction events
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of Participants Developing Oligohydramnios
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Number of Live Births
Endpoint domain: Mortality/survival
Primary endpoint: Number of Fetal Deaths/Stillbirths
Endpoint domain: Mortality/survival
Primary endpoint: Number of Fetal or Infant Major Malformations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Number of Fetal or Infant Deformations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Number of Fetal or Infant Disruptions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Triglyceride Levels at Week 12
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: High Density Lipoprotein-cholesterol (HDL-C) Levels at Week 12
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Total score of the Cardiff Anomalous Perceptions Scale (CAPS)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in Pain Levels
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Body Mass Density
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Bone Turnover Markers
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: The Short Form-36
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Maximum Plasma Concentration (Cmax) of Baseline Adjusted rhPTH(1-84)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Curve From the Time of Dosing to the Last Measurable Concentration (AUClast) of Baseline Adjusted rhPTH(1-84)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Terminal Half-Life (t1/2) of Baseline Adjusted rhPTH(1-84)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Reduction in Myopathic Pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Brief Pain Inventory (BPI) Severity at Exit
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Brief Pain Inventory (BPI) Interference at Exit
Endpoint domain: Life impact
Endpoint subdomain: Pain
Primary endpoint: alglucosidase alfa accumulation in breast milk
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: breast milk production and composition
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Geometric Mean Fold Rise in Serotype-Specific Pneumococcal IgG
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in dispositional mindfulness on the FFM Scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in verbal memory on the CVLT
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in interoceptive mindfulness on the MAIA scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: blood cell levels of p11
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Reduction of wrinkle severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: failure of treatment modality
Endpoint domain: Adverse events/effects
Primary endpoint: Change in overall skin texture and appearance of abdominal striae
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Accuracy of Noninvasive Sensors
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: FAZ Area Change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Macular Capillary Density Change at Full Retinal Thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: O2 Production in Neutrophils
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Adverse events registrations
Endpoint domain: Adverse events/effects
Primary endpoint: complete response rate (CR/CRu)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Level of BPE on breast MRI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Area Under the Curve (AUC) of total symptom score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Strengths & Difficulties Questionnaire (SDQ) scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in Paediatric Quality of Life Inventory (PedsQL V4.0) scores
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change in Knowledge of Autism Questionnaire (KAS) scores
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change in Goal Based Outcomes (GBOs) scores
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Mean daily PaO2 to FiO2 ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Oxygenation differences (PaO2/FiO2 ratio)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Pain scores on rest
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of subjects achieving serum HAI antibody titer of 1:40 or greater
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Successful Self-administration of Third Dose at Week 8 - Autoinjector With Standard Label + Pictogram
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Successful Self-administration of Third Dose at Week 8 - Autoinjector With Standard Label Only
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of pediatric urolithiasis
Endpoint domain: Mortality/survival
Primary endpoint: Rate of Maximal Fat Oxidation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Incidence of ISHLT primary graft dysfunction grade 3
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Difference in total testosterone levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Difference in free testosterone levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Difference in mean daily hot flushes score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Probability of Treatment Failure at 6 Months
Endpoint domain: Mortality/survival
Primary endpoint: Change from Baseline in CHOP-INTEND Total Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from Baseline in Neurological Examination Outcomes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Improvement of Symptoms Associated With Benign Prostatic Hyperplasia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of corneal hysteresis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in plasma levels of inflammatory markers (cytokines and CRP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in diversity and levels of fecal microbes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Change in behavioral responses (symptoms)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Area Under the Concentration-Time Curve (AUC0-t)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Concentration-Time Curve (AUC0-inf)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Performance of MD Anderson Symptom Inventory (MDASI)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Th2 Cytokine levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Maximum observed concentration (Cmax) of Febuxostat and Colchicine from plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the concentration-time curve (AUC) of Febuxostat and Colchicine from plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Apparent terminal half-life (t1/2) of Febuxostat and Colchicine from plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: change in expression of inflammatory mediators
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes